Clinical Trial Update: Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oxaliplatin in combination with capecitabine for relapsed/refractory carcinoma of unknown primary site; the study is completed and resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of Unknown Primary

Drugs mentioned

• Eloxatin (oxaliplatin)
• Xeloda (capecitabine)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Neoplasms, Unknown Primary | Phase 2 | Status: COMPLETED | Results posted: 2013-10-21